Finding new ways to treat neurodegenerative diseases
The Neurology Department at the Medical College of Georgia at Augusta University focuses on clinical research, treatment and support for patients
with movement and memory disorders.
As we age, our bodies begin to break down, causing physical and mental decline. These
declines can be difficult to deal with for both patients and caregivers. The goal
of the movement and memory section of the Neurology Department is to help patients
live longer, healthier, lives by stopping the progress of neurodegeneration. We do
this through training for the next generation of neurologists and neurosurgeons, research
and trials into innovative therapies for treatment of movement and memory disease,
and education for the future leaders in the field of movement and memory disorders.
Our movement disorders section manages 1 of the 33 prestigious comprehensive Parkinson's
Disease Centers of Excellence in the United States.
Memory Assessment Center
AU Health’s Alzheimer’s Program is a part of Georgia Memory Net and functions as a
Memory Assessment Center (MAC) in cooperation with Emory University. The goal is to
offer early detection of Alzheimer’s disease to patients in our area.
DBS neuromodulation is provided to appropriately selected patients with medically
resistant select movement disorders.
Beyond the Diagnosis: The Latest in Parkinson’s Medications and Surgical Treatments
We are actively involved in cutting-edge research and clinical trials with the goal
of improving the quality of life for our patients with memory and movement disorders.
Neurology teams-up with geriatric psychiatry, neuropsychology to conduct clinical
research by offering:
Patients the chance to participate in clinical trials for Alzheimer’s research.
Families the opportunity to enroll in research projects focusing on how genetics influence
Alzheimer's disease and other neurological disorders.
Every year, a half-million new cases of Alzheimer’s disease are diagnosed in the United
States. Nearly six million people are living with Alzheimer’s right now; by 2050,
that number is expected to more than double to nearly 14 million.